Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 9Biopsy 5Specimen Handling 4Prednisone 4Nivolumab 4Magnetic Resonance Spectroscopy 4fludarabine 3Vincristine 3Etoposide 3Doxorubicin 3Brentuximab Vedotin 3sodium-iodide symporter 2pembrolizumab 2fludarabine phosphate 2cemiplimab 2alectinib 2X-Rays 2Whole-Body Irradiation 2Stem Cell Transplantation 2Rituximab 2Positron-Emission Tomography 2Photons 2Mycophenolic Acid 2Immunoglobulin G 2Filgrastim 2Disulfides 2Cyclosporine 210-propargyl-10-deazaaminopterin 2treosulfan 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × AFM13 × 1 year × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡